Anika Therapeutics (ANIK) 10-Q2016 Q1 Quarterly report

Filed: 3 May 16, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accelerated, accelerating, aiding, alleviate, American, announced, approach, ASR, attributableto, August, bank, broader, buildout, CDER, classification, commericial, composed, comprised, Consorzio, constituting, constructing, construction, continuum, criteria, cuff, decision, degenerative, deliver, delivered, depleted, deposit, di, differentiated, direct, discount, Dollar, driven, earliest, elbow, equipment, experienced, expertise, final, fluid, Fluviale, footnote, foreseeable, foundation, function, global, globe, guidance, human, importantly, improve, improving, inception, incurred, Industriale, knee, landlord, Latin, launch, law, LLC, main, maximize, methodology, millionfor, Morgan, NDA, noncurrent, organization, overuse, owner, palliative, pay, Porto, practical, preliminary, premarket, proceeding, program, reclassification, reconstruct, regeneration, regulation, releveling, repetitive, replacement, replenishing, repurchase, repurchased, reset, restore, retained, retrospective, retrospectively, reversed, rotator, separately, settled, settlement, simplification, spine, standard, Stanley, steroid, suggest, supplement, synovial, synthetic, tendon, territorial, theFixed, transition, traumatic, Ultimately, uncertainty, Union, virtually, withdraw, ZIP, Zona

Removed: added, adhesion, aforementioned, AMVISC, April, assigning, base, Bausch, Boehringer, CMS, code, Coding, collected, considerably, core, Corporation, deduction, depending, DePuy, developed, diminishing, division, domestic, earned, equal, event, exclusive, exclusively, exercise, exercised, expand, expired, favorable, fixing, fulfillment, fully, Genzyme, healing, Healthcare, HYALOSPINE, HYVISC, IDE, incentive, Ingelheim, intrinsic, investment, issuance, January, large, license, licensing, litigation, Lomb, low, marketing, Medicaid, Medicare, Medline, milestone, Mitek, multiple, national, obtaining, past, pilot, pivotal, prevention, Procedure, production, reacquired, reflective, reimbursement, relating, represented, resolved, resolving, Restated, satisfy, scale, service, size, smaller, sourced, spinal, standalone, steadily, subsidiary, surgery, System, termination, unrecognized, upfront, varied

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ANIK similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 10.3

LEASE AMENDMENT AGREEMENT

Between

FIDIA FARMACEUTICI S.P.A. with registered office in Abano Terme (PD), via

Ponte della Fabbrica 3/A, Italy, V.A.T. No. 00204260285 (hereinafter "Fidia")

and

FIDIA ADVANCED BIOPOLYMERS S.r.l. with registered office in Abano Terme

(PD), via Ponte della Fabbrica 3/B, Italy, V.A.T. No. 03641500289 (hereinafter "FAB")

(hereinafter jointly referred to as the "Parties" and each one as a "Party")

WHEREAS

on December 30, 2009, Fidia and FAB entered into a lease agreement (the "Agreement") related to the lease of certain Property (as defined in the Agreement);

Fidia and FAB hereby agree as follows:

Definitions included in the Agreement shall have the same meaning in this Lease Amendment Agreement.

With effect as of September 20, 2010, Annex A to the Agreement is replaced by the revised Annex A attached to this Lease Amendment Agreement.

With effect as of September 20, 2010, Recital (C) to the Agreement is hereby amended as follows:

"the Lessor is the owner of the premises located at Abano Terme (PD), Via Ponte della Fabbrica 3/A and 3/B, registered with the NCT F. 10mapp. 632 and NCEU F. 10mapp. 632, as described by the extract from the Land Registry and maps as per Annex A hereto and identified as follows (the "Property"):

(1)

portion of the building named F2 ("Building F2 – Maps 0008_59 e 0008_02") per mq 380 for warehouse use;

(2)

portion of the building named "Istituto di Ricerca" (LR1 – Maps 0005 e 0006) for mq 1,174 for laboratories and production facility Tissue Tech and for mq 1,268 for office (ground floor and first floor);".

-1-

With effect as of September 20, 2010:

the table in Section 3.1, is replaced by the following table:

Area	Mq.	Monthly rent/mq (Euro)	Monthly rent (Euro)
Istituto di Ricerca (LR1 - Maps 0005 e 006) - Offices Warehouse ("Building F2 –Map 0008_59")	1,268	14.29	18,119
	373	5.11	1,906
Warehouse (“Building F2 – Map 0008_02”)	7	14.29	100
Istituto di Ricerca (LR1 - Map 0005)- Research Laboratories	655	17.05	11,168
Istituto di Ricerca (LR1 - Map 006)- Production facility Tissue Tech	519	17.05	8,849
Amount	2,822		41,042

And, b) the total amount in line to of Section 31 from September 20, 2010 is Euro 41,042.

-2-

IN WITNESS WHEREOF, the parties have executed or caused this Lease Amendment Agreement to be executed.

Abano Terme, September 20, 2010

FIDIA FARMACEUTICI S.P.A.

By:/s/ Antonio Germani

Antonio Germani, Chief Executive Officer

FIDIA ADVANCED BIOPOLYMERS S.R.L.

By:/s/ Charles H. Sherwood, Ph.D.

Charles Sherwood, President

-3-

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.